Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28088669 | 0.82 | TSHR (0.45) | TSHRNFKB1CYP2C19 | |
| SCHEMBL16369930 | 0.81 | TSHR (0.45) | TSHRNFKB1CYP2C19 | |
| SCHEMBL10574423 | 0.80 | TSHR (0.43) | TSHRNFKB1CYP2C19 | |
| SCHEMBL8613670 | 0.80 | TSHR (0.43) | TSHRNFKB1CYP2C19 | |
| SCHEMBL16391215 | 0.76 | TSHR (0.41) | TSHRNFKB1CYP2C19 | |
| SCHEMBL16391217 | 0.76 | TSHR (0.37) | TSHRNFKB1CYP2C19 | |
| SCHEMBL28448964 | 0.75 | TSHR (0.43) | TSHRNFKB1CYP2C19 | |
| SCHEMBL9067554 | 0.75 | TSHR (0.48) | TSHRNFKB1CYP2C19 | |
| SCHEMBL8527302 | 0.73 | TSHR (0.42) | TSHRNFKB1CYP2C19 | |
| SCHEMBL2278363 | 0.73 | TSHR (0.42) | TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | TSHR 4427/4885NFKB1 2449/4885CYP2C19 4064/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | TSHR 4427/4885NFKB1 2449/4885CYP2C19 4064/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | TSHR 4357/4885NFKB1 2206/4885CYP2C19 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.